Neuroprotection from complement-mediated inflammatory damage
- PMID: 15681806
- DOI: 10.1196/annals.1332.010
Neuroprotection from complement-mediated inflammatory damage
Abstract
Several neurodegenerative disorders, such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease, are associated with inflammatory damage. The complex process of neuroinflammation involves various components of the immune system and the central nervous system. Particularly, brain astrocytes and microglial cells generate several inflammatory mediators like cytokines, leukotrienes, superoxide radicals, eicasonoids, and the components of the complement cascade. Complement plays an important role in the etiology of most of the neuroinflammatory disorders. To prevent long-term dysfunction inflammation in the central nervous system must be modulated with neuroprotective agents such as nonsteroidal anti-inflammatory drugs, steroids, phenolic thiazoles, nitrones, catechins, nitric oxide synthetase inhibitors, flavonoids, and phosphodiesterase inhibitors. Few drugs are found to be effective and their therapeutic benefit is hampered by side effects. Most of the neuroprotective agents are free radical scavengers and many inhibit only one or two aspects of inflammation. The complement inhibitory activity of most of these agents is either unknown or not established. Thus, there is doubt regarding their therapeutic value in most of the inflammatory disorders in which complement plays a major role. In this context the role of a multifunctional protein, vaccinia virus complement control protein (VCP), is quite significant as it may play a pivotal role in the treatment of several neuroinflammatory disorders. VCP is known to inhibit both complement pathways involved in inflammation. It is also known to inhibit cytokines and chemokines in inflammation. Our recent studies on rats demonstrate that VCP administration inhibits macrophage infiltration, reduces spinal cord destruction, and improves motor skills associated with spinal cord injury, establishing VCP as a strong candidate for neuroprotection. Thus, complement inhibitors such as VCP can serve as neuroprotective agents in inflammation associated with several neurodegenerative disorders.
Similar articles
-
Herbal complement inhibitors in the treatment of neuroinflammation: future strategy for neuroprotection.Ann N Y Acad Sci. 2005 Nov;1056:413-29. doi: 10.1196/annals.1352.020. Ann N Y Acad Sci. 2005. PMID: 16387706 Review.
-
Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury.Ann N Y Acad Sci. 2004 Dec;1035:165-78. doi: 10.1196/annals.1332.011. Ann N Y Acad Sci. 2004. PMID: 15681807
-
The brain as a target for inflammatory processes and neuroprotective strategies.Ann N Y Acad Sci. 2007 Dec;1122:23-34. doi: 10.1196/annals.1403.002. Ann N Y Acad Sci. 2007. PMID: 18077562 Review.
-
Inflammation and the degenerative diseases of aging.Ann N Y Acad Sci. 2004 Dec;1035:104-16. doi: 10.1196/annals.1332.007. Ann N Y Acad Sci. 2004. PMID: 15681803 Review.
-
Role of complement in neurodegeneration and neuroinflammation.Mol Immunol. 2007 Feb;44(5):999-1010. doi: 10.1016/j.molimm.2006.03.007. Epub 2006 May 15. Mol Immunol. 2007. PMID: 16698083 Review.
Cited by
-
Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice.J Neuroinflammation. 2007 May 2;4:13. doi: 10.1186/1742-2094-4-13. J Neuroinflammation. 2007. PMID: 17474994 Free PMC article. Clinical Trial.
-
Another barrier to regeneration in the CNS: activated macrophages induce extensive retraction of dystrophic axons through direct physical interactions.J Neurosci. 2008 Sep 17;28(38):9330-41. doi: 10.1523/JNEUROSCI.2488-08.2008. J Neurosci. 2008. PMID: 18799667 Free PMC article.
-
Viral-derived complement inhibitors: current status and potential role in immunomodulation.Exp Biol Med (Maywood). 2017 Feb;242(4):397-410. doi: 10.1177/1535370216675772. Epub 2016 Oct 26. Exp Biol Med (Maywood). 2017. PMID: 27798122 Free PMC article. Review.
-
Complement C3 Inhibition Modulates Neurodegeneration in Chronic Traumatic Brain Injury.J Neurosci. 2018 Aug 15;38(33):7201-7203. doi: 10.1523/JNEUROSCI.1011-18.2018. J Neurosci. 2018. PMID: 30111576 Free PMC article. No abstract available.
-
Association between leukotriene-modifying agents and suicide: what is the evidence?Drug Saf. 2011 Jul 1;34(7):533-44. doi: 10.2165/11587260-000000000-00000. Drug Saf. 2011. PMID: 21663330 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous